GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Price-to-Free-Cash-Flow

Gland Pharma (NSE:GLAND) Price-to-Free-Cash-Flow : N/A (As of Apr. 24, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Price-to-Free-Cash-Flow?

As of today (2025-04-24), Gland Pharma's share price is ₹1478.70. Gland Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0.00. Hence, Gland Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Gland Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

NSE:GLAND' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 39.89   Med: 172.69   Max: 5553.37
Current: 41.07

During the past 7 years, Gland Pharma's highest Price-to-Free-Cash-Flow Ratio was 5553.37. The lowest was 39.89. And the median was 172.69.

NSE:GLAND's Price-to-Free-Cash-Flow is ranked worse than
67.37% of 518 companies
in the Drug Manufacturers industry
Industry Median: 24.645 vs NSE:GLAND: 41.07

Gland Pharma's Free Cash Flow per Share for the three months ended in Dec. 2024 was ₹0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was ₹0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 15.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 26.30% per year.

During the past 7 years, Gland Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 75.30% per year. The lowest was -34.90% per year. And the median was 32.20% per year.


Gland Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Gland Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Price-to-Free-Cash-Flow Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - 104.28 200.43 148.28 50.79

Gland Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 50.79 - - -

Competitive Comparison of Gland Pharma's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Price-to-Free-Cash-Flow falls into.


;
;

Gland Pharma Price-to-Free-Cash-Flow Calculation

Gland Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1478.70/0
=N/A

Gland Pharma's Share Price of today is ₹1478.70.
Gland Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Gland Pharma  (NSE:GLAND) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Gland Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma Headlines

No Headlines